| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Lacto-N-fucopentaose II does not have a specific biological target; instead, it functions as a glycan that interacts with various lectins, antibodies, and receptors involved in host-microbe interactions and cell recognition processes. It is a human milk oligosaccharide (HMO) that may modulate the infant gut microbiome and immune system. LNFP II serves as a hapten for human Lewis blood group determinants and is a component of the CA 19-9 tumor marker.
|
|---|---|
| ln Vitro |
In vitro, Lacto-N-fucopentaose II is used to study host-microbe interactions and cell recognition processes. It serves as a substrate for glycosyltransferases and a ligand for lectins and antibodies. The compound's unique structure, featuring terminal fucose residues, makes it valuable for investigating glycan-mediated interactions. LNFP II is also used as a standard in glycan analysis and as a hapten for immunological studies.
|
| ln Vivo |
In vivo, Lacto-N-fucopentaose II is a component of human milk and may contribute to the development of the infant gut microbiome and immune system. It may act as a prebiotic, promoting the growth of beneficial bacteria such as Bifidobacteria. However, specific in vivo efficacy data for purified LNFP II are limited, as it is primarily used as a research tool in glycan biology.
|
| Enzyme Assay |
The non-cellular assay for Lacto-N-fucopentaose II involves studying its interactions with lectins, antibodies, or glycosyltransferases using surface plasmon resonance (SPR), enzyme-linked immunosorbent assay (ELISA), or glycan microarray analysis. The compound is immobilized on a solid surface, and the binding of specific proteins (e.g., lectins or antibodies) is measured. The affinity and specificity of the interactions are determined.
|
| Cell Assay |
The cellular assay for Lacto-N-fucopentaose II involves treating cultured cells (e.g., intestinal epithelial cells or immune cells) with the compound and measuring its effects on cell signaling, adhesion, or immune responses. The compound is added to the culture medium at various concentrations, and the expression of cytokines, adhesion molecules, or other markers is measured by qPCR or ELISA. The effects on bacterial adhesion or growth are also assessed in co-culture models.
|
| Animal Protocol |
In the in vivo efficacy study, Lacto-N-fucopentaose II is administered orally to animal models, such as mice or piglets, to study its effects on the gut microbiome and immune system. The compound is typically added to the drinking water or food. Fecal samples are collected for microbiome analysis by 16S rRNA sequencing. Immune parameters are measured in blood and intestinal tissues.
|
| ADME/Pharmacokinetics |
Lacto-N-fucopentaose II has a molecular weight of 853.77 and a molecular formula of C₃₂H₅₅NO₂₅. It is a complex oligosaccharide that is soluble in water. The compound should be stored at room temperature for transport and at appropriate conditions for long-term storage. Lacto-N-fucopentaose II should be handled with appropriate laboratory safety precautions.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Lacto-N-fucopentaose II has not been extensively characterized in the published literature. As a human milk oligosaccharide, it is generally considered safe and is not known to be toxic. However, comprehensive toxicology data are limited, and the compound is not approved for clinical use. Lacto-N-fucopentaose II should be handled with appropriate laboratory safety precautions.
|
| References | |
| Additional Infomation |
Lactose-N-fucopentose-2 is an oligosaccharide.
Lacto-N-fucopentaose II (LNFP II) is a human milk oligosaccharide that has been studied for its role in host-microbe interactions, cell recognition, and as a hapten for Lewis blood group determinants. It is a component of the CA 19-9 tumor marker, which is used in the diagnosis of pancreatic and biliary malignancies. LNFP II is a valuable research tool for studying glycan biology, the infant gut microbiome, and immune system development. The compound is not approved for clinical use and is strictly a research tool. |
| Molecular Formula |
C32H55NO25
|
|---|---|
| Molecular Weight |
853.77
|
| Exact Mass |
853.306
|
| CAS # |
21973-23-9
|
| PubChem CID |
168012
|
| Appearance |
White to off-white solid powder
|
| Density |
1.71g/cm3
|
| Boiling Point |
1264.6ºC at 760mmHg
|
| Flash Point |
718.6ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.668
|
| LogP |
-9.9
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
25
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
58
|
| Complexity |
1290
|
| Defined Atom Stereocenter Count |
24
|
| SMILES |
C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)NC(=O)C)O[C@H]4[C@H]([C@H](O[C@H]([C@@H]4O)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)CO)O)CO)O)O)O
|
| InChi Key |
FKADDOYBRRMBPP-QKPOUJQKSA-N
|
| InChi Code |
InChI=1S/C32H55NO25/c1-8-16(42)20(46)22(48)30(51-8)56-26-14(7-38)54-29(15(33-9(2)39)27(26)57-31-23(49)21(47)18(44)12(5-36)52-31)58-28-19(45)13(6-37)53-32(24(28)50)55-25(11(41)4-35)17(43)10(40)3-34/h3,8,10-32,35-38,40-50H,4-7H2,1-2H3,(H,33,39)/t8-,10-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20+,21-,22-,23+,24+,25+,26+,27+,28-,29-,30-,31-,32-/m0/s1
|
| Chemical Name |
N-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4R,5R)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide
|
| Synonyms |
Lnfp-II; Lnfp II; Lacto-N-fucopentaose II
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~292.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1713 mL | 5.8564 mL | 11.7128 mL | |
| 5 mM | 0.2343 mL | 1.1713 mL | 2.3426 mL | |
| 10 mM | 0.1171 mL | 0.5856 mL | 1.1713 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
